publication date: Dec. 11, 2020

Clinical Roundup

Some postmenopausal women with common breast cancer may forgo chemotherapy

Postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from a clinical trial presented at the 2020 San Antonio Breast Cancer Symposium.

These findings may save tens of thousands of postmenopausal women each year the time, money, and harmful side effects that come with chemotherapy infusions.

This is the first evidence in a randomized phase III trial that postmenopausal women with HR-positive, HER2-negative breast cancer that has spread to one to three lymph nodes can safely forgo chemotherapy if their recurrence score on a genomic tumor tissue test is 25 or less.

The trial also demonstrated, after a median of five years of follow-up, that premenopausal women with the same disease characteristics benefited from chemotherapy.

The study, SWOG S1007, known as RxPONDER, was supported by NCI, designed and led by SWOG Cancer Research Network, and conducted by the NCI National Clinical Trials Network. RxPONDER was an international effort, conducted at 632 sites in nine countries—the United States, Canada, Mexico, Colombia, Ireland, France, Spain, Korea, and Saudi Arabia.

“Every day in clinics around the world, physicians wrestle with the question of how to best treat women with this common form of breast cancer,” lead author Kevin Kalinsky, SWOG investigator and director of the Glenn Family Breast Center at the Winship Cancer Institute of Emory University, said in a statement “These results are practice-changing and demonstrate that postmenopausal women can … Continue reading Some postmenopausal women with common breast cancer may forgo chemotherapy

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.